Home About Us Industry Report Store Resources Contact us

Tumor Treating Fields Market Research Report 2024

Tumor Treating Fields Market Global Industry Analysis and Forecast (2024-2032) By Product Type (Transducer Arrays, Tumor Treating Field Generators, Others), By Indication (Glioblastoma Multiforme, Non-small Cell Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Mesothelioma, Brain Metastasis, Others), By Frequency (Low Frequency, Intermediate Frequency), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others) and Region.

0/5
( 0 votes )

Report ID: 321

Categories: Healthcare

Format :

Summary TOC Segmentation Methodology

Tumor Treating Fields Market Synopsis

Tumor Treating Fields Market Size Was Valued at USD 332.9 Million in 2023 and is Projected to Reach USD 1236.84 Million by 2032, Growing at a CAGR of 15.7 % from 2024-2032.

Tumor Treating Fields (TTFields) are electric fields that prevent cancer cell survival and tumor growth, without impacting healthy cells. TTFields therapy is delivered to the tumor using arrays that are placed on the patient’s skin, surrounding the tumor site, without the need for invasive procedures. Tumor Treating Fields (TTFields) are electric fields that exert physical forces to disrupt cellular processes critical for cancer cell viability and tumor progression.

  • The frequency of the electric fields falls between 100 kHz and 500 kHz, making it too high for tissue stimulation and too low for ionizing or significant heating effects. TTFields are administered at a precise frequency depending on the type of cancer cells being targeted, enabling effective treatment of various cancer types. The most effective TTFields frequency is 150 kHz for NSCLC and pancreatic cancer cells and 200 kHz for ovarian cancer cells. TTFields specifically focus on the unique characteristics of cancer cells like their rate of division and shape, while having minimal impact on healthy cells.
  • TTFields treatment is administered in a non-invasive manner to the area of the tumor through a portable medical tool (NovoTTF-200;) which includes a field generator and arrays that are positioned on the patient's skin. The efficiency of TTFields therapy in fighting cancer hinges on the frequency, intensity, and duration of treatment, making it advisable to apply TTFields therapy for a minimum of 18 hours per day to optimize its benefits. The novel medical device, NovoTTF-100, was 6 lbs., but the restructured & updated NovoTTF-200 device now weighs 2.7 lbs. to improve & enhance patient acceptance, satisfaction, and usage
  • Ongoing research and development initiatives to broaden TTFields' application to other cancer types characterize the market. To improve overall patient results, clinical trials, and research are still being conducted to see if TTFields work well in conjunction with other conventional therapies. The market is expanding as a result of rising usage by healthcare providers and regulatory clearances.
  • The market for TTFields is propelled not just by its therapeutic potential but also by an increasing recognition of the necessity for tailored and various treatment alternatives for cancer. Patients looking for non-invasive options to standard cancer therapy may find the technology appealing due to its relatively moderate side-effect profile and lack of invasiveness. The market is expected to grow as more research is conducted and data is gathered, potentially making TTFields a standard part of cancer treatment plans for a wider range of cancers. All things considered, the TTFields market represents a potential new frontier in the rapidly changing field of cancer therapies, providing a distinct and focused method to prevent the growth of tumors while reducing harmful effects on healthy tissues.

TOP Key Player:

Boston Scientific Corporation (U.S.), Varian Medical Systems, Inc. (U.S.), Johnson & Johnson (U.S.), GE Healthcare (U.S.), Accuray Incorporated (U.S.), Stryker Corporation (U.S.), Zimmer Biomet Holdings, Inc. (U.S.), Roche (U.S.), Pfizer Inc. (U.S.), Merck & Co., Inc. (U.S.), Bristol Myers Squibb (U.S.), Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Novocure Limited (Jersey), Medtronic plc (Ireland), Elekta AB (Sweden), Siemens Healthineers (Germany), Philips Healthcare (Netherlands), AstraZeneca plc (England), GlaxoSmithKline plc (England), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan)

Tumor Treating Fields Market Trend Analysis

TTFields in Promising Non-Invasive Glioblastoma Treatment

  • TTFields are a hopeful non-invasive treatment for glioblastoma, the most aggressive form of brain cancer. TTFields therapy utilizes low-intensity, intermediate-frequency alternating electrical fields applied via cutaneous transducer arrays to influence charged molecules and inhibit cancer cell growth. This method has increased the lifespan of patients with newly diagnosed and recurrent GBM, as well as mesothelioma, resulting in FDA recognition.
  • Currently, clinical trials are investigating the potential of TTFields in treating different solid tumors like mesothelioma, lung cancer, and pancreatic cancer. TTFields affect not just the mitotic apparatus but also disturb DNA repair, cell permeability, and immunological responses, indicating a wide range of actions. As the knowledge of how TTFields work improves, more opportunities for using them in clinical settings arise, which could lead to substantial market growth.
  • By considering all things, the TTFields market signifies a possible new frontier in the swiftly shifting field of cancer therapies, providing a distinct and focused method to prevent the growth of tumors while reducing harmful effects on healthy tissues.

Role of TTFields Therapy in Cancer Treatment and Regulatory Approvals

  • The market for Tumor Treating Fields (TTFields) is set to experience continuous growth in the next few years, fueled by the rising incidence of cancer worldwide. An increasing number of cases of brain cancer, especially, as well as the approval of new uses by regulators, will continue to support the implementation of TTFields therapy. This new treatment method uses changing electric fields to interrupt the division of cancer cells, providing a non-invasive choice for patients. Although TTField devices and therapy are expensive, their benefits of better patient outcomes and fewer side effects make them an attractive option for patients and healthcare providers, despite the potential hindrance to market expansion.
  • The TTFields market is projected to be led by North America, thanks to strong awareness and significant investments in research and development by U.S.-based key market players. At the same time, the Asia Pacific region is expected to see rapid growth, supported by a growing patient population and better access to advanced cancer treatments in developing countries. Opportunities for increasing market reach consist of launching new products targeted towards various cancer types and improving device design to increase patient comfort and adherence. With increasing awareness and availability, the TTFields market is poised to make significant advances in the global battle against cancer.

Tumor Treating Fields Market Segment Analysis:

Tumor Treating Fields Market Segmented by Product Type, Indication, Frequency, End User.

By Product, Transducer Arrays Segment Is Expected to Dominate the Market During the Forecast Period.

  • The transducer arrays sector is the top player in the Tumor Treating Fields (TTFields) market, with the biggest market share. These arrays are essential in TTFields treatment, which is becoming more acknowledged for its effectiveness in managing specific types of tumors. Transducer arrays, widely used in medical settings, play a crucial role in applying TTFields directly to the tumor site. This technique utilizes electromagnetic fields to interfere with the division of cancer cells, providing a non-intrusive treatment choice.
  • The market favors transducer arrays due to their essential role in providing accurate and focused TTFields treatment. Transducer arrays, being disposable components, guarantee treatment sessions that are both hygienic and efficient, following strict medical standards. The significant growth in the market share of the segment is largely due to the effective management of various cancers by their widespread use. As research and development progress in improving TTFields therapy technology, it is anticipated that transducer arrays will remain important in advancing cancer treatment methods.

By Indication, The Glioblastoma Multiforme Segment Held the Largest Share.

  • Glioblastoma multiforme (GBM) has always been the top product in the market for Tumor Treating Fields (TTFields) because of its high occurrence rate and critical demand for treatment. GBM, the most frequent and aggressive primary brain tumor in adults, presents substantial difficulties as existing treatments provide minimal survival advantages. Common treatments generally contain extensive surgery, radiation therapy, and the most common and renowned chemotherapy with temozolomide (TMZ), but the average survival time is still only around 10-16 months, with slight chances of long-term survival.
  • TTFields therapy is a noteworthy progression in treating GBM as it administers low-intensity (1-3 V/cm), intermediate-frequency (100-300 kHz) alternating electric fields through transducer arrays placed on the skin. This non-invasive method has proven to increase life expectancy when combined with traditional treatments. TTFields are effective in GBM because they can inhibit cancer cell growth and impact biological activities such as DNA repair and cell permeability. Clinical trials have confirmed its advantages, resulting in FDA approval and continued research of TTFields in different types of cancer, underscoring its crucial role in improving treatment choices for patients with this aggressive disease.

Tumor Treating Fields Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast Period

  • North America dominates the Tumor Treating Fields (TTFields) market, holding over 42.9% of the market share in I2023, Multiple factors contribute to this leadership role. The high rate of cancer cases in North America creates a strong need for advanced treatments such as TTFields. Additionally, the area is home to a strong presence of leading market participants engaged in the research, advancement, and introduction of TTFields technology. These companies enhance the region's competitive advantage by investing strategically in healthcare technology and creating innovative solutions.
  • North America has a strong healthcare system and both healthcare providers and patients are well-informed about TTFields therapy. This understanding facilitates the early uptake and incorporation of TTFields into medical settings, additionally strengthening market expansion. Therefore, North America is not only at the forefront in market size but also plays a crucial role in driving progress in cancer treatment technologies, establishing a strong presence in the global TTFields market.

Active Key Players in the Tumor Treating Fields Market

  • Boston Scientific Corporation (U.S.)
  • Varian Medical Systems, Inc. (U.S.)
  • Johnson & Johnson (U.S.)
  • GE Healthcare (U.S.)
  • Accuray Incorporated (U.S.)
  • Stryker Corporation (U.S.)
  • Zimmer Biomet Holdings, Inc. (U.S.)
  • Roche (U.S.)
  • Pfizer Inc. (U.S.)
  • Merck & Co., Inc. (U.S.)
  • Bristol Myers Squibb (U.S.)
  • Eli Lilly and Company (U.S.)
  • AbbVie Inc. (U.S.)
  • Novocure Limited (Jersey)
  • Medtronic plc (Ireland)
  • Elekta AB (Sweden)
  • Siemens Healthineers (Germany)
  • Philips Healthcare (Netherlands)
  • AstraZeneca plc (England)
  • GlaxoSmithKline plc (England)
  • Sanofi (France)
  • Takeda Pharmaceutical Company Limited (Japan)

Key Industry Developments in the Tumor Treating Fields Market:

  • In January 2024, Varian, a company owned by Siemens Healthineers, and Nova Scotia Health have revealed an innovative 10-year, CAD 175 million multi-disciplinary oncology partnership (MDOP). This partnership seeks to enhance cancer treatment throughout Nova Scotia by simplifying the patient experience from diagnosis to recovery. The collaboration aims to improve cancer workflows and precision treatments in Nova Scotia, where cancer rates are higher than average among its 1 million inhabitants. By utilizing Siemens Healthineers' knowledge, the effort highlights a dedication to enhancing healthcare through innovation and enhancing survival rates in the area.
  • In June 2024, Boston Scientific Corporation confirmed a definitive deal to acquire Silk Road Medical, Inc., a top provider of medical equipment for avoiding strokes in individuals with carotid artery issues. Silk Road Medical's unique platform is centered on TCAR, a minimally invasive procedure for revascularizing the carotid artery. The purchase, worth around $1.16 billion at $27.50 per share, highlights Boston Scientific's dedication to improving its cardiovascular offerings and enhancing its abilities to address important medical concerns regarding stroke prevention.

Global Tumor Treating Fields Market

Base Year:

2023

Forecast Period:

2023-2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 332.9 Mn.

Forecast Period 2024-32 CAGR:

15.7 %

Market Size in 2032:

USD 1236.84 Mn.

Segments Covered:

By Product Type:

  • Transducer Arrays
  • Tumor Treating Field Generators
  • Others

By Indication

  • Glioblastoma Multiforme
  • Non-small Cell Lung Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Mesothelioma
  • Brain Metastasis
  • Others

By

Frequency

  • Low Frequency
  • Intermediate Frequency

By End User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

Frequently Asked Questions

What would be the forecast period in the Tumor Treating Fields Market research report?

The forecast period in the Tumor Treating Fields Market research report is 2024-2032.

Who are the key players in the Tumor Treating Fields market?

Boston Scientific Corporation (U.S.), Varian Medical Systems, Inc. (U.S.), Johnson & Johnson (U.S.), GE Healthcare (U.S.), Accuray Incorporated (U.S.), Stryker Corporation (U.S.), Zimmer Biomet Holdings, Inc. (U.S.), Roche (U.S.), Pfizer Inc. (U.S.), Merck & Co., Inc. (U.S.), Bristol Myers Squibb (U.S.), Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Novocure Limited (Jersey), Medtronic plc (Ireland), Elekta AB (Sweden), Siemens Healthineers (Germany), Philips Healthcare (Netherlands), AstraZeneca plc (England), GlaxoSmithKline plc (England), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan) And Other Major Players.

What are the segments of Artificial Intelligence in the Aviation market?

Tumor Treating Field is segmented into Product Type, Indication, Frequency, and End User. By Product, the market is categorized into Transducer Arrays, Tumor Treating Field Generators, and Others. By Indication, the market is categorized into Glioblastoma Multiforme, Non-small Cell Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Mesothelioma, Brain Metastasis, and Others. By Frequency, the market is categorized into Low Frequency and intermediate Frequency. By End User, the market is categorized into Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others. By region, it is analyzed across North America (U.S.; Canada; Mexico), Europe (Germany; U.K.; France; Italy; Russia; Spain, etc.), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).

What is the Tumor Treating Fields Market?

Tumor Treating Fields (TTFields) are electric fields that prevent cancer cell survival and tumor growth, without impacting healthy cells. TTFields therapy is delivered to the tumor using arrays that are placed on the patient’s skin, surrounding the tumor site, without the need for invasive procedures. Tumor Treating Fields (TTFields) are electric fields that exert physical forces to disrupt cellular processes critical for cancer cell viability and tumor progression.

How big is the Tumor Treating Fields Market?

Tumor Treating Fields Market Size Was Valued at USD 332.9 Million in 2023 and is Projected to Reach USD 1236.84 Million by 2032, Growing at a CAGR of 15.7 % from 2024-2032.

Select Licence Type

Single User

US$ 3200

Corporate User

US$ 4500

Excel Datapack

US$ 1500

Yearly Membership/Subscription

Connect with our sales team

Why Pristine Intelligence LLP

100%

Customer
Satisfaction

24x7+

Availability - we are always
there when you need us

200+

Fortune 50 Companies trust
Pristine Intelligence LLP

80%

of our reports are exclusive
and first in the industry

100%

more data
and analysis

1000+

reports published
till date